Incretin therapy for diabetes mellitus type 2

Image

Incretin therapy for diabetes mellitus type 2

Among the gastrointestinal hormones, the incretins: glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 have attracted interest because of their importance for the development and therapy of type 2 diabetes and obesity. New agonists and formulations of particularly the GLP-1 receptor have been developed recently showing great therapeutic efficacy for both diseases. The status of the currently available GLP-1 receptor agonists (GLP-1RAs) and their strengths and weaknesses were analysed in a study. Their ability to also reduce cardiovascular and renal risk was analysed. The most recent development of orally available agonists and of very potent monomolecular co-agonists for both the GLP-1 and GIP receptor. The GLP-1RAs are currently the most efficacious agents for weight loss, and show potential for further efficacy in combination with other food-intake-regulating peptides. Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy.

Endocrinology and Metabolism: Open Access is a peer reviewed journal which focuses on the publication of current research and developments on the endocrine glands and its secretions with their coordination with metabolism and reproduction.

Endocrinology and Metabolism: Open Access Journal is using Editorial Tracking System to maintain quality and transparency to the author in the peer-review process. Review processing will be performed by the editorial board members of the Journal Endocrinology and Metabolism: Open Access or by Reviewers (outside experts in the field). Two independent reviewer’s approval (Minimum reviewer’s approval) followed by editor approval is obligatory for acceptance of any manuscript excluding an editorial.

Journal is now accepting manuscripts for volume 5 for year 2021. We publish minimum of 5 and maximum of 20 articles per issue every month. Submissions to our journal are given high priority during the process.

Submit your manuscript at:

https://www.imedpub.com/submissions/endocrinology-metabolism-open-access.html 

You may also send the manuscript as an attachment to mail endometabol@emedscholar.com

Media Contact
Eliza Grace
Associate Managing Editor
Endocrinology and Metabolism: Open Access
E-Mail: 
endometabol@emedscholar.com